Purchase this article with an account.
N. Ishida, T. Akaishi, H. Kurashima, M. Mieda, M. Nakamura; Comparison of IOP-Lowering Effect of Tafluprost and Latanoprost in Ocular Hypotension Monkeys. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3823.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Tafluprost is a new-generation prostanoid FP-receptor agonist for the treatment of glaucoma. This compound has exhibited more potent IOP-lowering effects than latanoprost in ocular normotensive and hypertensive animals. The purpose of this study is to compare the IOP-lowering efficacy of tafluprost and latanoprost in ocular hypotensive monkeys.
This study was performed by crossover design. Nine male selected Cynomolgus monkeys (baseline IOP: 13-14 mmHg) which had been trained to accept instillation of eye drops and IOP measurement in conscious were used. Tafluprost 0.0015% (once a day), latanoprost 0.005% (once a day) or saline was topically applied to one eye for 7 days. IOP measurements were performed 0, 2, 4, 6, and 8 hour after topical application of test solutions on day 1 and day 7.
Both tafluprost and latanoprost showed IOP-reducing effect in ocular hypotension monkeys. The mean diurnal IOP on day 7 in saline group, latanoprost group and tafluprost group was 13.9 ± 0.3 mmHg, 13.0 ± 0.4 mmHg and 12.2 ± 0.3 mmHg, respectively. The maximal reductions in IOP achieved by tafluprost and latanoprost were 3.2 ± 0.3 mmHg (22% reduction) and 2.2 ± 0.3 mmHg (15% reduction), respectively. Although latanoprost did not reduce IOP at the trough time-point, tafluprost did significantly reduce trough IOP compared with saline group.
Tafluprost revealed a potent IOP-reducing effect compared with latanoprost in ocular hypotension monkey eyes. This result suggesting that tafluprost may be an effective medicine for patients with low-tension glaucoma.
This PDF is available to Subscribers Only